This issue is about how to read an evidence claim, using the sector's most fashionable vocabulary as the worked example. We are not going to tell you whether any treatment works. We are going to set out what would have to be true for the claim to be supportable.
The first question about any product in this space is what it legally is. Depending on composition, presentation and intended purpose, a product may be a medicine, a medical device, a cosmetic product, or, where human cells or tissues are involved, may fall within a different framework again with its own licensing requirements.
Those routes carry materially different evidential requirements before market access. Conflating them, which the word regenerative does effortlessly, obscures the single most important fact about a product.
ObservedThe MHRA is the UK regulator across medicines and medical devices, and the applicable framework for a product depends on its composition, presentation and intended purpose rather than on how it is marketed.AnalysisA category label that spans several regulatory routes is useful to marketing precisely because it prevents the buyer from asking which route applies.The question that cuts through all of it: what is this product classified as in the UK, and under which route did it reach the market. If the supplier cannot answer, the clinic cannot answer, and the clinic is the one making the claim to the patient.
New treatment vocabulary produces a predictable search pattern: a spike in branded and semi technical queries, almost no institutional content, and clinic pages arriving to fill the gap within weeks.
That is the worst possible information environment. High curiosity, low institutional supply, and every available answer written by someone selling the answer. It is also where generative systems perform worst, because there is nothing authoritative in the corpus to anchor to.
AnalysisThe lag between a treatment entering the market and institutional sources addressing it is the window in which the sector's least supportable claims are made and indexed.SpeculationContent written during that window persists long after the evidence position becomes clearer, which means the marketing record for a treatment often outlives its accuracy.If you publish about a new treatment, publish what is not yet known alongside what is claimed. That page ages well. The confident one does not.
Clinical bodies move slowly on new treatments, and that slowness is usually characterised in the sector as being behind the times. It is more accurately described as waiting for evidence.
Where a professional body has not issued a position on a treatment, the correct inference is that no position has been issued. It is not evidence of endorsement and it is not evidence of concern, and it gets presented as both depending on who is speaking.
ObservedProfessional and clinical bodies publish positions and guidance where they have assessed a question. The absence of a published position is a fact about the body's output, not about the treatment.Silence from an institution is data about the institution. Treating it as a verdict, in either direction, is the most common evidential error in this sector's commentary.
Patients now arrive asking for a named treatment rather than describing a problem, and they arrive having read mechanism explanations that are considerably more confident than the literature.
That inverts the consultation. Instead of assessing a concern and proposing an approach, the practitioner is being asked to supply a specified product, which is a retail interaction wearing clinical clothing.
AnalysisA patient requesting a named treatment has already made the assessment the consultation exists to perform. Restoring the assessment is the practitioner's job and it is commercially awkward.SpeculationAs treatment vocabulary spreads faster through social channels, the proportion of product first consultations seems likely to rise. We have no way to measure it and neither does anyone quoting a figure.The reset is a question, not a lecture: what is it you are hoping will change. It moves the conversation back to the concern, and it is the only reliable way to find out whether the requested treatment addresses it.
"Stimulates your own collagen." A mechanism claim requiring evidence for the specific product, in the specific application, at the specific dose. "Clinically proven." Proven for what outcome, measured how, in whom, over what period, and compared against what.
"Backed by science." Not a claim, a mood. "Used in medicine for decades." Possibly true and possibly irrelevant, because use in one indication is not evidence for use in another. "Natural." Neither a regulatory category nor a safety property.
ObservedObjective claims in advertising require substantiation appropriate to the claim, and a claim about a specific product in a specific application requires evidence about that product in that application.The useful test for any evidence claim is four words long: measured what, in whom. If a claim cannot survive those four words, it is not an evidence claim, it is a slogan with a footnote.
New treatment categories are attractive to clinics for a reason that has little to do with clinical merit: they are not yet price anchored.
An established procedure has a market price that patients can compare in seconds. A new one does not, which temporarily restores pricing power. That is a legitimate commercial observation and it also explains why adoption of new categories is frequently faster than the evidence supporting them.
AnalysisThe economic incentive to be early is strongest exactly when the evidence is weakest. That is a structural problem in the sector, not a comment on any individual practitioner.SpeculationPrice anchoring in new categories appears to arrive within a small number of years as adoption spreads. The window is real and it is not permanent.If a treatment's principal commercial attraction is that patients cannot compare its price, that is worth knowing about your own decision to offer it. It does not make the treatment wrong. It does mean the reason you adopted it is not the reason you will give.
The pattern in this sector is consistent: a new category arrives, marketing outruns evidence, institutional sources catch up, claims are narrowed, and the category settles into a defensible but smaller position.
What is different now is the permanence of the record. Claims made during the enthusiastic phase are indexed, archived and retrievable, and increasingly they are retrievable by systems that will reproduce them long after the clinic has quietly stopped saying them.
AnalysisThe reputational cost of over claiming has lengthened considerably, because the internet's memory has been supplemented by systems that summarise it.SpeculationWe expect claim discipline to become a competitive advantage rather than a compliance chore, for exactly that reason. It is a mechanism argument and we cannot measure it.Write claims you will still be comfortable with when the evidence position clarifies. That is a lower bar than it sounds and most of the sector is failing it.